Printer Friendly

GLIATECH APPOINTS SCHERING-PLOUGH EXECUTIVE VICE PRESIDENT OF PRODUCT DEVELOPMENT

 CLEVELAND, June 14 /PRNewswire/ -- Gliatech Inc. today announced it has appointed Michael Zupon Ph.D., as vice president, product development and operations. In this newly created position, Dr. Zupon will be responsible for the establishment of Gliatech's product development and manufacturing capabilities on a worldwide basis. The company's lead product, ADCON-L, is currently under clinical testing in Europe for the prevention of excess scarring following disc surgery.
 "Mike brings to Gliatech a wealth of experience in product formulation and development," said Thomas O. Oesterling, Ph.D., president and chief executive officer of Gliatech. "This knowledge will be important to Gliatech's expansion of the ADCON technology to other surgical indications, as well as to product development of the company's cognition modulation drug candidates."
 Previously, Dr. Zupon, 38, spent 12 years at Schering-Plough Corporation (NYSE: SP) in a variety of product development positions, most recently as director, drug delivery and technology assessment. In this position he directed the dosage form development projects with external collaborators and evaluated emerging technologies and products related to drug delivery technologies for potential licensing. During his development career at Schering-Plough, Dr. Zupon directed formulation development, package development and process validation and transfer to manufacturing of numerous ethical pharmaceutical and biotechnology products, including the highly successful alpha interferon product Intron A. Dr. Zupon is the holder of six patents (five additional patents pending), covering a wide array of dosage forms including sustained release parenterals, topicals iontophoresis and transdermals.
 Dr. Zupon received his bachelor of science and Ph.D. degrees from the University of Utah College of Pharmacy and also received a master of business administration degree from its Graduate School of Business.
 Gliatech was formed in 1988 to discover, develop and commercialize therapeutic products based on an understanding of properties of glial cells, a major component of the nervous system.
 -0- 6/14/93
 /CONTACT: Thomas O. Oesterling, Ph.D., president of Gliatech, 216-831-3200, or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, for Gliatech/


CO: Gliatech Inc. ST: Ohio IN: MTC SU: PER

CK-TS -- NY035 -- 1551 06/14/93 10:44 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 14, 1993
Words:345
Previous Article:CACI AWARDED NEW CONTRACT FROM SECRETARY OF THE ARMY REVENUE POTENTIAL OF $40 MILLION OVER FIVE YEARS
Next Article:TAUBMAN CENTERS DECLARES REGULAR QUARTERLY DIVIDEND
Topics:


Related Articles
SCHERING-PLOUGH HEALTHCARE PRESIDENT DAVID COLLINS ELECTED CHAIRMAN OF NDMA
GLIATECH APPOINTS WALCER VICE PRESIDENT OF BUSINESS DEVELOPMENT AND MARKETING
AUTOIMMUNE ELECTS HUGH A. D'ANDRADE OF SCHERING-PLOUGH TO BOARD OF DIRECTORS
SCHERING-PLOUGH BOARD OF DIRECTORS ELECTS WYSZOMIERSKI NEW CHIEF FINANCIAL OFFICER; OTHER FINANCIAL EXECUTIVE CHANGES ANNOUNCED
SCHERING-PLOUGH BOARD OF DIRECTORS ELECTS JOHN E. NINE CORPORATE VICE PRESIDENT
SCHERING-PLOUGH APPOINTS BRYCE PRESIDENT OF HEALTHCARE PRODUCTS, ZAHN AS PRESIDENT, SCHERING LABORATORIES
Schering-Plough Board of Directors Elects Richard Jay Kogan Chairman of Board And CEO, Raul E. Cesan as President and Chief Operating Officer.
Schering-Plough Board of Directors Elects Richard Jay Kogan Chairman of Board And CEO, Raul E. Cesan as President and Chief Operating Officer.
Schering-Plough Announces Executive Changes in R&D.
Schering-Plough Announces Changes In Executive Finance Positions.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters